Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Sarissa Capital Management urges Amarin shareholders to vote the BLUE proxy card ahead of the general meeting on February 28, 2023. Shareholders should ensure their votes are submitted by February 21, 2023. Sarissa's presentation highlights inaccuracies in Amarin's statements aimed at protecting its board, advocating for the election of Sarissa’s nominees and the removal of Chairman Per Wold-Olsen. Shareholders are encouraged to refrain from using Amarin’s WHITE proxy card, with additional details available on Sarissa's website and through its proxy solicitor, D.F. King & Co., Inc.
Amarin Corporation (NASDAQ: AMRN) sent a letter to shareholders urging them to vote "AGAINST" Sarissa Capital's proposals during the upcoming General Meeting set for February 28, 2023. The company criticized Sarissa for spreading misleading information and attempting to take control of the board with underqualified nominees. Key points include Sarissa's historical negative impact on shareholder value, with a median total shareholder return of -24% at companies with Sarissa-nominated directors. Amarin emphasizes its commitment to maximizing shareholder value and has initiated cost-saving measures, achieving $50 million in reductions in 2022.
Sarissa Capital Management has launched a dedicated website for Amarin Corporation shareholders, emphasizing the importance of voting with the BLUE proxy card by February 21, 2023, at 11:59 PM EST. The proxy card will allow shareholders to support Sarissa's slate of nominees at Amarin's upcoming general meeting on February 28, 2023. Sarissa advises against using Amarin’s WHITE proxy card. Shareholders can access important documents via the SEC website or Sarissa's site for further instructions on voting and to view their presentation.
Amarin Corporation plc (NASDAQ: AMRN) urges shareholders to vote against all proposals by Sarissa Capital Management at the upcoming General Meeting on February 28, 2023. The company emphasizes its newly appointed Board, led by Chairman Per Wold-Olsen, is executing a transformative strategy to enhance shareholder value. Key achievements include securing six international regulatory approvals in 2022, stabilizing U.S. revenue for four consecutive quarters, and implementing a $100 million annual cost savings plan. Amarin's leadership asserts that Sarissa’s proposed changes could jeopardize the company's progress.
Sarissa Capital Management is urging Amarin Corporation (NASDAQ: AMRN) shareholders to support their nominees for the board and remove Chairman Per Wold-Olsen at the upcoming general meeting on February 22, 2023. They emphasize the 64% stock decline in 2022, which resulted in over $840 million lost in shareholder value due to alleged mismanagement. Sarissa argues that adding their nominees will help maximize shareholder value based on their successful track record in the healthcare sector. They contend that the current leadership is obstructing accountability and shareholder representation, further advocating for the vote before key deadlines.
Amarin Corporation plc (NASDAQ: AMRN) has filed definitive proxy materials with the SEC for its upcoming General Meeting on February 28, 2023. Shareholders are urged to vote "AGAINST" Sarissa Capital Management's proxy proposals, arguing that Sarissa lacks a constructive plan and has presented an underqualified slate of nominees. Over the past 18 months, Amarin has revamped its leadership and board, focusing on geographic expansion and enhancing operational efficiency. The company is confident in achieving up to $1 billion in revenue opportunities through its strategies, despite facing generic competition in the U.S.
Amarin Corporation (NASDAQ: AMRN) announced that Medsafe in New Zealand has granted regulatory approval for VAZKEPA (icosapent ethyl) to reduce cardiovascular (CV) event risks in statin-treated adults with high CV risk and elevated triglycerides. This marks the seventh approval for the VASCEPA/VAZKEPA franchise in key international markets since 2022. Cardiovascular disease significantly impacts New Zealand, with about 175,000 adults affected. Amarin is now seeking commercialization partners to support VAZKEPA's introduction in New Zealand.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the SVB Securities Global Biopharma Conference, scheduled for February 14, 2023, at 10:40 a.m. ET. This virtual conference will span from February 13-16, 2023. The presentation will be available via webcast and will be archived on the company's website.
Amarin focuses on cardiovascular disease management and is committed to advancing treatment options.
Amarin Corporation plc (NASDAQ:AMRN) responds to Sarissa Capital's intervention, highlighting a comprehensive and independent board refreshment process. Amarin emphasizes its recognition of shareholder frustration due to U.S. IP losses and outlines a new strategy alongside a revamped management team. The board has successfully negotiated pricing for VAZKEPA® in five European markets and has secured six international regulatory approvals. Despite facing generic competition, Amarin maintains approximately 60% market share, a competitive advantage in the industry. The company aims to continue stabilizing revenue and advancing its fixed-dose combination program.
Sarissa Capital Management has expressed deep concern over Amarin's board governance, highlighting the absence of shareholder representation. In 2022, Amarin's stock plummeted by over two-thirds, translating to a loss of more than $840 million in equity for its shareholders. Key issues include delays in the European launch, challenges in securing reimbursement in Germany, and ineffective management responses that led to significant capital destruction. Sarissa, as Amarin's largest shareholder, is pushing for a special meeting to remove Chairman Per Wold-Olsen and appoint new directors to enhance shareholder interests.